Finding and Drugging the Vulnerabilities of RAS-Dependent Cancers

Kinase inhibitors have ushered in the era of targeted therapy, but their utility to date is primarily limited to cancers bearing oncogenic kinase mutations. Two papers in this issue ( Luo et al., 2009; Scholl et al., 2009) could change this landscape by uncovering kinase-specific vulnerabilities in...

Full description

Saved in:
Bibliographic Details
Published inCell Vol. 137; no. 5; pp. 796 - 798
Main Author Sawyers, Charles L.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 29.05.2009
Subjects
Cell Line, Tumor
Humans
Mutation
Neoplasms - drug therapy
Protein Kinase Inhibitors - pharmacology
ras Proteins - genetics
ras Proteins - metabolism
Online AccessGet full text

Cover

More Information
Summary:Kinase inhibitors have ushered in the era of targeted therapy, but their utility to date is primarily limited to cancers bearing oncogenic kinase mutations. Two papers in this issue ( Luo et al., 2009; Scholl et al., 2009) could change this landscape by uncovering kinase-specific vulnerabilities in tumors with RAS mutations.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-3
ObjectType-Commentary-1
ISSN:0092-8674
1097-4172
DOI:10.1016/j.cell.2009.05.011